Finance

Lists
Why is 302440 down 4.26%?
Dive Deeper
302440:KRX
SK Bioscience Co Ltd
₩38,200.00
-4.26%
(-1,700.00) 1D
Nov 18, 3:30:06 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 302440...
Open
₩39,450
High
₩40,100
Low
₩38,050
Mkt. cap
3.00T
Avg. vol.
104.97K
Volume
98.61K
52-wk high
₩55,700
52-wk low
₩31,500
EPS
-₩1,259
Shares outstanding
78.46M
No. of employees
917
Open
₩39,450
High
₩40,100
Low
₩38,050
Mkt. cap
3.00T
Avg. vol.
104.97K
Volume
98.61K
52-wk high
₩55,700
52-wk low
₩31,500
EPS
-₩1,259
Shares outstanding
78.46M
No. of employees
917
News stories
From web sources and news partners
ING Sprinters
ING Sprinters
·
12 hours ago
De AEX Index breekt steun
ZeelandNet, startpagina van Zeeland
ZeelandNet, startpagina van Zeeland
·
12 hours ago
AEX-index lager, chipbedrijven dalen in aanloop cijfers Nvidia
Profile
SK Bioscience is a South Korean biotechnology company that produces vaccines and other products and is a subsidiary of SK Chemicals. Wikipedia
About SK Bioscience Co Ltd
CEOAhn Jae-yong
Employees917
FoundedJul 1, 2018
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
150.76B
184.19B
168.61B
155.71B
Cost of goods sold
118.04B
179.39B
153.75B
114.18B
Cost of revenue
118.04B
179.39B
153.75B
114.18B
Research and development expenses
19.88B
17.75B
20.98B
14.23B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.51B
33.59B
32.36B
37.12B
Operating expense
52.09B
56.40B
59.39B
57.26B
Total operating expenses
170.14B
235.80B
213.15B
171.44B
Operating income
-19.37B
-51.61B
-44.54B
-15.74B
Other non operating income
-637.92M
-1.13B
-364.73M
317.28M
EBT including unusual items
-15.58B
-21.32B
-47.85B
-16.44B
EBT excluding unusual items
-23.07B
-48.65B
-46.46B
-18.45B
Income tax expense
-36.66B
35.09B
-11.68B
-2.35B
Effective tax rate
235.33%
-164.62%
24.42%
14.30%
Other operating expenses
281.98M
532.04M
261.38M
654.37M
Net income
24.48B
-57.96B
-33.33B
-17.89B
Net profit margin
16.24%
-31.47%
-19.77%
-11.49%
Earnings per share
313.00
-740.00
-425.00
-229.00
Interest and investment income
2.75B
6.81B
4.88B
3.07B
Interest expense
-2.67B
-2.04B
-3.73B
-4.24B
Net interest expenses
84.41M
4.77B
1.15B
-1.17B
Depreciation and amortization charges
1.15B
1.49B
2.67B
1.89B
EBITDA
3.25B
-25.91B
-19.11B
8.72B
Gain or loss from assets sale
-547.83M
-30.91B
105.62M
352.00K
Upcoming events
AI content may include mistakes. Learn more
Google apps